Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Lymphoblastic Leukemia: early-phase trial registry
58 of 132 indexed Acute Lymphoblastic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #88 of 28,707 conditions by registered trial count.
132 US clinical trials · 58 currently recruiting · #88 of 28,707 conditions by registered trial count
Acute Lymphoblastic Leukemia: 132 US clinical trials tracked, 58 recruiting.
Acute Lymphoblastic Leukemia is the subject of 132 registered US clinical trials on ClinicalTrials.gov, 58 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 97 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 15 of these trials.
Enrollment posture brief
Registry condition acute-lymphoblastic-leukemia
OPEN 58 | RECR 44% | LATE 8 | EARLY 97 | RANK #88 | SPON 15
Volume-matched condition peers
Nearest open-share peer: Small Lymphocytic Lymphoma (44% recruiting · 82 trials)
Acute Lymphoblastic Leukemia lists 58 open slots (44% of 132 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Lymphoblastic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Lymphoblastic Leukemia is recruiting above its size-band peers.
58 of 132 indexed trials (43.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Acute Lymphoblastic Leukemia trials is spread across many organizations.
City of Hope Medical Center accounts for 15 of 132 trials (11.4%). 57 distinct sponsors appear on at least one study for this condition label.
-
Most Acute Lymphoblastic Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 132 trials that report a genuine target (sentinel values excluded). 83 of those (62.9%) plan for fewer than 100 participants.
-
Acute Lymphoblastic Leukemia research is mostly interventional.
116 interventional and 16 observational studies make up this index (87.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
132 total, page 1 of 3
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
Columbia University
NCT05929976
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
NCT05334069
European Prospective Investigation Into Childhood Cancer
Columbia University
NCT05375617
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
PedAL BCU
NCT04726241
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
St. Jude Children's Research Hospital
NCT06289673
Pharmacogenomics of Asparaginase Induced Hepatotoxicity
University of Southern California
NCT03568266
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Syndax Pharmaceuticals
NCT04065399
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Janssen Research & Development
NCT04811560
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
Columbia University
NCT05963971
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems
NCT03802695
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
NCT03314974
Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
Children's Oncology Group
NCT05014165
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology
NCT04067336
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT06059391
MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence
Roswell Park Cancer Institute
NCT06323044
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
National Cancer Institute (NCI)
NCT06364423
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
NCT06533748
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT05442515
Childhood Cancer Survivors' Affective Response to Exercise
St. Jude Children's Research Hospital
NCT05763290
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center
NCT03970096
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
NCT02727803
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT03263572
Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
Masonic Cancer Center, University of Minnesota
NCT05025774
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Fred Hutchinson Cancer Center
NCT03128034
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
City of Hope Medical Center
NCT03422731
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT05735717
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT03779854
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
NCT05031897
Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
Northwestern University
NCT03932903
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT04195633
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
H. Lee Moffitt Cancer Center and Research Institute
NCT06144606
A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
National Cancer Institute (NCI)
NCT05621291
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
NCT06013423
A Study of Revumenib and Mezigdomide in People With Leukemia
Memorial Sloan Kettering Cancer Center
NCT07356154
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Meryx
NCT04872478
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT03810196
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT06308588
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
City of Hope Medical Center
NCT06128070
A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
NCT07400029
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
City of Hope Medical Center
NCT06815003
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
NCT06195891
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
NCT06777979
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
University of Colorado, Denver
NCT05535855
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
City of Hope Medical Center
NCT06575296
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
St. Jude Children's Research Hospital
NCT06847269
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago
NCT04747912
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
NCT02508038
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Northside Hospital
NCT05519579
Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia
Children's Hospital of Orange County
NCT05501899
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Joshua Sasine, MD, PhD
NCT05887167
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 49 |
| Phase 2 | 48 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Lymphoblastic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Lymphoblastic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Lymphoblastic Leukemia page
132 registered trials, 58 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 58 Acute Lymphoblastic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- City of Hope Medical Center sponsors the most Acute Lymphoblastic Leukemia trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Lymphoblastic Leukemia condition card totals 132 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.